ARTICLE | Clinical News
OvaRex: Continued Phase IIb trial
March 22, 1999 8:00 AM UTC
AltaRex Corp. (TSE:AXO), Waltham, Mass. Product: OvaRex Business: Cancer Therapeutic category: Immune stimulation Target: CA125 antigen Description: Monoclonal antibody against CA125 that stimulates...